(PROK) ProKidney - Ratings and Ratios
Cell Therapy, Kidney Disease, Diabetes, Rilparencel
PROK EPS (Earnings per Share)
PROK Revenue
Description: PROK ProKidney
ProKidney Corp. is a clinical-stage biotechnology company pioneering a cell therapy platform to treat various chronic kidney diseases. The companys lead candidate, rilparencel, is an autologous selected renal cells (SRC) therapy currently in Phase 3 and Phase 2 trials for patients with moderate to severe chronic kidney disease and diabetes. With a cryopreserved version of rilparencel in development, the company is poised to advance its clinical programs and potentially revolutionize the treatment landscape for chronic kidney diseases.
From a market perspective, ProKidney Corp.s common stock (PROK) is listed on NASDAQ, providing a liquid market for investors. As a biotechnology company, ProKidney operates in a highly competitive and innovative sector, with a strong focus on research and development. The companys headquarters in Winston-Salem, North Carolina, is strategically located near major research institutions, facilitating collaboration and talent acquisition.
Analyzing the technical data, the stocks recent price action indicates a potential bullish trend, with the 20-day SMA at $0.81 and the 50-day SMA at $0.79, both below the current price of $0.90. However, the 200-day SMA at $1.48 suggests a longer-term bearish trend. The ATR of 0.09 (9.80% volatility) indicates a relatively high level of price volatility. Considering the 52-week high of $2.99 and low of $0.51, the stock has shown significant price fluctuations.
From a fundamental perspective, ProKidney Corp.s market capitalization stands at $1.81 billion, with a Return on Equity (RoE) of 6.94%. The absence of a P/E ratio and forward P/E ratio is not surprising, given the companys focus on R&D and lack of commercialized products. As the company advances its clinical programs, investors will be watching for key milestones and updates on rilparencels progress.
Forecasting the stocks performance, we can anticipate potential price movements based on the technical and fundamental data. If rilparencel demonstrates positive results in its ongoing trials, we can expect a surge in the stock price, potentially breaking through the 200-day SMA at $1.48. Conversely, any setbacks or negative news may lead to a decline in the stock price, potentially testing the 52-week low of $0.51. With a high ATR and significant price fluctuations, investors should be prepared for potential volatility.
Additional Sources for PROK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
PROK Stock Overview
Market Cap in USD | 1,812m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Biotechnology |
IPO / Inception | 2022-07-12 |
PROK Stock Ratings
Growth Rating | -75.1 |
Fundamental | - |
Dividend Rating | 0.0 |
Rel. Strength | 85.7 |
Analysts | 4.14 of 5 |
Fair Price Momentum | 0.34 USD |
Fair Price DCF | - |
PROK Dividends
Currently no dividends paidPROK Growth Ratios
Growth Correlation 3m | -8.7% |
Growth Correlation 12m | -90.2% |
Growth Correlation 5y | -74.6% |
CAGR 5y | -21.97% |
CAGR/Max DD 5y | -0.23 |
Sharpe Ratio 12m | -0.01 |
Alpha | 31.28 |
Beta | 3.737 |
Volatility | 151.15% |
Current Volume | 343149.6k |
Average Volume 20d | 1102.8k |
Stop Loss | 3.6 (-3.5%) |
As of July 09, 2025, the stock is trading at USD 3.73 with a total of 343,149,610 shares traded.
Over the past week, the price has changed by +560.18%, over one month by +280.61%, over three months by +630.08% and over the past year by +68.78%.
No, based on ValueRay´s Analyses, ProKidney (NASDAQ:PROK) is currently (July 2025) a stock to sell. It has a ValueRay Growth Rating of -75.09 and therefor a clear technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PROK is around 0.34 USD . This means that PROK is currently overvalued and has a potential downside of -90.88%.
ProKidney has received a consensus analysts rating of 4.14. Therefore, it is recommended to buy PROK.
- Strong Buy: 4
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, PROK ProKidney will be worth about 0.4 in July 2026. The stock is currently trading at 3.73. This means that the stock has a potential downside of -89.28%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 4 | 7.2% |
Analysts Target Price | 4.7 | 25.2% |
ValueRay Target Price | 0.4 | -89.3% |